

ASX ANNOUNCEMENT 9 January 2013

CEO Update and US Investor Presentation

Bionomics Limited (ASX: BNO) (ADR: BMICY) today announced its CEO, Dr Deborah Rathjen, has provided a company update at the Biotech Showcase 2013 in San Francisco, USA.

The presentation highlighted the progress of Bionomics' proprietary and partnered discovery and development pipeline including:

- An update on the status of BNC105 clinical trials, in particular the Phase I component of the ongoing Phase II clinical trial in patients with metastatic kidney cancer:
 - o The combination BNC105 + Afinitor is safe and well tolerated
 - o 12 patients were enrolled across 4 BNC105 dose levels (4 -16mg/m²)
 - o 8 patients achieved stable disease
 - o 7 patients received at least 15 treatment cycles (45 weeks, 11.25 months)
 - 1 patient is still on study having received 23 treatment cycles (69 weeks, 17.25 months)
- The commencement of a US clinical trial by partner Ironwood Pharmaceuticals of IW-2143 (BNC210). As the trial progresses it is anticipated that a US\$2 million milestone payment to Bionomics will be triggered.
- Competitive positioning of BNC375, Bionomics' drug candidate for addressing cognitive impairment in Alzheimers disease and other conditions.
- Progress of Bionomics' cancer stem cell asset BNC101 (formerly ET101) towards clinical trials. BNC101 binds selectively to LGR5; LGR5 marks tumour-initiating cells in colon and gastric cancer. LGR5 is also highly overexpressed in colon, ovarian, liver, breast, lung and other solid tumours. High expression of LGR5 in colon cancer has been associated with tumour recurrence and poor prognosis.

The presentation also highlighted that Bionomics anticipates receiving \$4.2 million from the Australian Government under the R&D Tax Incentive.

As part of activities surrounding the 31st JP Morgan Healthcare Conference, briefings will also be given to US institutional investors and pharmaceutical companies.

The presentation can be found on Bionomics' website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

The Trout Group Lauren Glaser +1 646 378 2972 lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is an Australian based international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and autoimmune disorders, several of which are in or approaching clinical development stage. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development for the treatment in a range of solid tumour types, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143(BNC210), our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deal with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.